STAT3 and urinary bladder carcinoma: It is also worth noting that our discovery about SRC inhibition by HME implies that, besides STAT3, additional signaling pathways downstream of SRC, such as AKT and MAPK [44,45,46,47,48], are likely involved in HME’s anticancer mechanisms of action in the context of bladder cancer.